Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Primary Care
Published in: BMC Primary Care 1/2007

Open Access 01-12-2007 | Study protocol

Protocol for the THREAD (THREshold for AntiDepressants) study: a randomised controlled trial to determine the clinical and cost-effectiveness of antidepressants plus supportive care, versus supportive care alone, for mild to moderate depression in UK general practice

Authors: Judy Chatwin, Tony Kendrick, the THREAD Study Group

Published in: BMC Primary Care | Issue 1/2007

Login to get access

Abstract

Background

Depression guidelines in the UK recommended a policy of watchful waiting for mild depression due to a lack of evidence for the effectiveness of antidepressant treatment for mild cases. However there has been relatively little research carried out in primary care to help establish the severity threshold at which antidepressant treatment is effective and cost-effective.

Methods/Design

The THREAD (THREshold for AntiDepressants) study is a multi-centre randomised controlled trial designed to determine the clinical and cost effectiveness of a selective serotonin reuptake inhibitor (SSRI) plus general practitioner (GP) supportive care, versus supportive care alone, for mild to moderate depression in primary care. The aim is to recruit 300 patients from three centres (Southampton, London and Liverpool). Depressive symptoms will be assessed at baseline, 12 weeks and 26 weeks, using the 17-item Hamilton Depression Rating Scale (HDRS). Two severity sub-groups of patients will be recruited, with HDRS scores of 12–15, and 16–19. Possible predictors of response will be explored including life events and difficulties and alcohol consumption. Analysis of covariance, controlling for baseline value, severity group and centre will be used to estimate the overall treatment effectiveness (difference in HDRS score) at final follow up. The primary analysis will be by 'intention to treat' using double sided tests. The interaction between severity sub-group and treatment will be tested, and if appropriate, effects within separate severity sub-groups estimated. The economic analysis will compare the two treatment groups in terms of mean costs and cost-effectiveness.

Discussion

The results of this study will give GPs important information to help them determine the severity of depression at which antidepressant treatment is likely to be cost-effective.
Appendix
Available only for authorised users
Literature
1.
2.
Kendrick T, Stevens L, Bryant A, Goddard J, Stevens A, Raftery J, Thompson C: Hampshire Depression Project: Changes in the process of care and cost consequences. British Journal of General Practice. 2001, 51: 911-913.PubMedPubMedCentral
3.
Anderson IM, Nutt DJ, Deakin JFW: Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2000, 3-20.
4.
NHS National Institute for Clinical Excellence: Depression: Management of depression in primary and secondary care – Clinical Guideline 23. 1-12-2004
5.
Paykel ES, Hollyman JA, Freeling P, Sedgwick P: Predictors of therapeutic benefit from amitriptyline in mild depression: A general practice placebo-controlled trial. Journal of Affective Disorders. 1988, 14: 83-95. 10.1016/0165-0327(88)90075-4.CrossRefPubMed
6.
Barrett JE, Williams JW, Oxman TE, Katon W, Frank E, Hegel MT, Sullivan M, Schulberg HC: The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: background and research plan. General Hospital Psychiatry. 1999, 21: 260-273. 10.1016/S0163-8343(99)00023-7.CrossRefPubMed
7.
Barrett JE, Williams JW, Oxman TE, Frank E, Katon W, Sullivan M, Hegel MT, Cornell JE, Senqupta AS: Treatment of dysthymia and minor depression in primary care: a randomised trial in patients aged 18 to 59 years. Journal of Family Practice. 2001, 50: 405-412.PubMed
8.
Williams JW, Barrett JE, Oxman TE, Frank E, Katon W, Sullivan M, Cornell J, Senqupta A: Treatment of dysthymia and minor depression in primary care: a randomised controlled trial in older adults. Journal of American Medical Association. 2000, 284: 1519-1526. 10.1001/jama.284.12.1519.CrossRef
9.
Judd LL, Rapaport MH, Yonkers KA, Rush AJ, Frank E, Thase ME, Kupfer DJ, Plewes JM, Schettler PJ, Tollefson G: Randomized, Placebo-Controlled Trial of Fluoxetine for Acute Treatment of Minor Depressive disorder. The American Journal of Psychiatry. 2004, 161: 1864-1871. 10.1176/appi.ajp.161.10.1864.CrossRefPubMed
10.
Rapaport MH, Judd LL, Schettler PJ, Yonkers KA, Thase ME, Kupfer DJ, Frank E, Plewes JM, Tollefson GD, Rush AJ: A Descriptive Analysis of Minor Depression. American Journal of Psychiatry. 2002, 159: 637-643. 10.1176/appi.ajp.159.4.637.CrossRefPubMed
11.
Perahia DGS, Kajdasz DK, Walker DJ, Raskin J, Tylee A: Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. International Journal of Clinical Practice. 2006, 60: 613-620. 10.1111/j.1368-5031.2006.00956.x.CrossRefPubMedPubMedCentral
12.
World Health Organisation: The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva. 1993
13.
de Lima MS, Hotopf M, Wessely S: The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychological Medicine. 1999, 29: 1273-1289. 10.1017/S0033291799001324.CrossRefPubMed
14.
Paykel ES, Hollyman JA, Freeling P, Sedgwick P: Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. Journal of Affective Disorders. 1988, 83-95. 10.1016/0165-0327(88)90075-4.
15.
Paykel ES, Priest RG: Recognition and management of depression in general practice: consensus statement. British Medical Journal. 1992, 305: 1198-1202.CrossRefPubMedPubMedCentral
16.
Montgomery SA: Guidelines for treating depressive illness with antidepressants. Journal of Psychopharmacology. 1993, 19-23.
17.
School of Public Health UoLCfHEUoYaRURCoP: Effective Health Care Bulletin: The Treatment of Depression in Primary Care. 1993, York, Department of Health
18.
Regier DA, Farmer ME, Rae DS, Myers JK, Kramer M, Robins L, George LK, Karno M, Locke BZ: One-month prevalence of mental disorders in the United States and sociodemographic characteristics: The Epidemiologic catchment Area Study. Acta Psychiatrica Scandinavica. 1993, 88: 35-47.CrossRefPubMed
19.
20.
Bruce M, Takeuchi DT, Leaf PJ: Poverty and psychiatric status: longitudinal evidence from the New Haven epidemiologic catchment area study. Archives of General Psychiatry. 1991, 48: 470-474.CrossRefPubMed
21.
Kessler RC, Turner JB, House J: Intervening processes in the relationship between unemployment and health. Psychological Medicine. 1987, 17: 949-961.CrossRefPubMed
22.
Romans SE, Walton VA, McNoe B, Herbison GP, Mullen PE: Otago women's health survey 30-month follow up I: Onset patterns of non-psychotic psychiatric disorder. British Journal of Psychiatry. 1993, 163: 733-738.CrossRefPubMed
23.
Platt S, Martin C, Hunt S: The mental health of women with children living in deprived areas of Great Britain: the role of living conditions, poverty and unemployment. The Public Health Impact of Mental Disorder. Edited by: Goldberg D, Tantam D. 1990, Toronto: Hogrefe and Huber, 124-135.
24.
Brown GW, Harris T: Social origins of Depression: A Study of Psychiatric Disorder in Women. 1978, London: Tavistock Publications
25.
Brown GW, Bifulco A, Harris T: Life events, vulnerability and onset of depression: some refinements. British Journal of Psychiatry. 1987, 150: 30-42.CrossRefPubMed
26.
Oldehinkel AJ, Ormel J, Neeleman J: Predictors of time to remission from depression in primary care patients: do some people benefit more from positive life change than others?. Journal of Abnormal Psychology. 2000, 109: 299-307. 10.1037/0021-843X.109.2.299.CrossRefPubMed
27.
Harris T, Brown GW, Robinson R: Befriending as an intervention for chronic depression among women in an inner city 2. Role of fresh start experiences and baseline psychosocial factors in remission from depression. British Journal of Psychiatry. 1999, 174: 225-232.CrossRefPubMed
28.
Ronalds C, Creed R, Stone K, Webb S, Tomenson BM: Outcome of anxiety and depressive disorders in primary care. British Journal of Psychiatry. 1997, 427-433.
29.
Dowrick C, Buchan I: Twelve month outcome of depression in general practice: does detection or disclosure make a difference. British Medical Journal. 1995, 311: 1274-1276.CrossRefPubMedPubMedCentral
30.
Goldberg D, Privett M, Ustun B, Simon GE, Linden M: The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. British Journal of General Practice. 1998, 48: 1840-1844.PubMedPubMedCentral
31.
Lam DH, Green B, Power MJ, Checkley S: The impact of social cognitive variables on the initial level of depression and recovery. Journal of Affective Disorders. 1994, 32: 75-83. 10.1016/0165-0327(94)90065-5.CrossRefPubMed
32.
Garcia-Campayo J, Campos R, Marcos G, Perez-Echeverria MJ, Lobo A: Somatisation in primary care in Spain: II Differences between somatisers and psychologisers. British Journal of Psychiatry. 1996, 168: 348-353.CrossRefPubMed
33.
Mumford DB, Bavington JT, Bhatnagar KS, Hussain Y, Mirza S, Naraghi MM: The Bradford Somatic Inventory: A multi-ethnic inventory of somatic symptoms reported by anxious and depressed patients in Britain and the Indo-Pakistan Subcontinent. British Journal of Psychiatry. 1991, 158: 379-386.CrossRefPubMed
34.
Maier W: The Hamilton Depression Scale and its alternatives: a comparison of their reliability and validity. The Hamilton Scales. Edited by: Bech P, Coppen A. 1990, Berlin Heidelberg: Springer-Verlag, 64-71.CrossRef
35.
Paykel ES: Use of the Hamilton Depression Scale in General Practice. The Hamilton Scales. Edited by: Bech P, Coppen A. 1990, Berlin Heidelberg: Springer-Verlag, 40-47.CrossRef
36.
Potts MK, Daniels M, Burnam MA, Wells KB: A structured interview version of the Hamilton Depression Rating Scale; evidence of reliability and versatility of administration. Journal of Psychiatric Research. 1990, 24: 335-350. 10.1016/0022-3956(90)90005-B.CrossRefPubMed
37.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An Inventory for Measuring Depression. Archives of General Psychiatry. 1961, 4: 53-61.CrossRef
38.
Ware J, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey, manual and interpretation guide. 1993, Boston, Mass: The Health Institute, New England Medical Centre
39.
Brown GW, Harris T: Life Events and Illness. 1989, New York; London: Guilford Press; Unwin & Hyman
40.
Saunders JB, Aasland OG, Amundsen A, Grant M: Development of the alcohol use disorder identification test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption. Addiction. 1993, 88: 791-804. 10.1111/j.1360-0443.1993.tb02093.x.CrossRefPubMed
41.
Morisky DE, Green LW, Levine DM: Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence. Medical Care. 1986, 24: 67-74. 10.1097/00005650-198601000-00007.CrossRefPubMed
42.
Knapp M, Beecham J: Reduced list costings: examination of an informed short cut in mental health research. Health Economics. 1993, 2: 313-332.CrossRefPubMed
43.
Hollyman JA, Freeling P, Paykel ES, Bhat A, Sedgewick P: Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice. Journal of the Royal College of General Practice. 1988, 38: 393-397.
Metadata
Title
Protocol for the THREAD (THREshold for AntiDepressants) study: a randomised controlled trial to determine the clinical and cost-effectiveness of antidepressants plus supportive care, versus supportive care alone, for mild to moderate depression in UK general practice
Authors
Judy Chatwin
Tony Kendrick
the THREAD Study Group
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Primary Care / Issue 1/2007
Electronic ISSN: 2731-4553
DOI
https://doi.org/10.1186/1471-2296-8-2

Other articles of this Issue 1/2007

BMC Primary Care 1/2007 Go to the issue

Research article

Do general practitioners adhere to the guideline on infectious conjunctivitis? Results of the Second Dutch National Survey of General Practice

Research article

Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: A double-blind randomised placebo controlled 6-month trial

Research article

Buprenorphine versus dihydrocodeine for opiate detoxification in primary care: a randomised controlled trial

Research article

Chinese and white Canadian satisfaction and compliance with physicians

Research article

General Practitioners involvement in enteral tube feeding at home: a qualitative study

Research article

The gender specific frequency of risk factor and CHD diagnoses prior to incident MI: A community study